- Home
- KNSA vs DKL Comparison
KNSA vs DKL Comparison
Compare KNSA & DKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KNSA | DKL |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Natural Gas Distribution |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 2.8B |
| IPO Year | 2018 | 2012 |
Fundamental Metrics
Financial Performance| Metric | KNSA | DKL |
|---|---|---|
| Price | $56.40 | $51.86 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 3 |
| Target Price | ★ $60.86 | $53.67 |
| AVG Volume (30 Days) | ★ 800.5K | 48.0K |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 8.52% |
| EPS Growth | ★ 225.00 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $677,564,000.00 | N/A |
| Revenue This Year | $37.48 | $2.73 |
| Revenue Next Year | $17.87 | $6.82 |
| P/E Ratio | $211.00 | ★ $17.62 |
| Revenue Growth | ★ 60.09 | N/A |
| 52 Week Low | $25.71 | $37.50 |
| 52 Week High | $57.27 | $55.89 |
Technical Indicators
Market Signals| Indicator | KNSA | DKL |
|---|---|---|
| Relative Strength Index (RSI) | 74.22 | 53.19 |
| Support Level | $40.67 | $50.17 |
| Resistance Level | N/A | $55.20 |
| Average True Range (ATR) | 2.32 | 1.44 |
| MACD | 1.32 | 0.46 |
| Stochastic Oscillator | 95.15 | 61.54 |
Price Performance
Historical ComparisonAbout KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
About DKL Delek Logistics Partners
Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.